Share Search
Visit the Share Search
Oxford Biomedica strikes new license and supply agreements
13th Dec 2021 07:31
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.
Oxford Biomedica said on Monday that it had signed a new licence and supply agreement with Arcellx, a Maryland-based biotechnology company, granting it a non-exclusive licence to the group's LentiVector platform for application in select Arcellx CAR-T programmes as part of a three-year clinical supply agreement.
Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials and also allows for payments for the manufacture and supply of lentiviral vectors for commercial use.
Separately, the FTSE 250-listed firm agreed to an extension and update to its commercial supply Agreement with Novartis for the manufacture of its lentiviral vectors for several Novartis CAR-T products.
Oxford Biomedica said the pair had extended the terms of their commercial supply agreement to the end of 2028, with Oxford regaining the rights to its LentiVector platform relating to three CAR-T targets. Oxford Biomedica highlighted that it now also has the right to work with potential pharmaceutical and biotech partners other than Novartis across all CAR-T targets.
As of 0820 GMT, Oxford Biomedical shares were down 0.92% at 1,192.95p.
Oxford Biomedica said on Monday that it had signed a new licence and supply agreement with Arcellx, a Maryland-based biotechnology company, granting it a non-exclusive licence to the group's LentiVector platform for application in select Arcellx CAR-T programmes as part of a three-year clinical supply agreement.
Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials and also allows for payments for the manufacture and supply of lentiviral vectors for commercial use.
Separately, the FTSE 250-listed firm agreed to an extension and update to its commercial supply Agreement with Novartis for the manufacture of its lentiviral vectors for several Novartis CAR-T products.
Oxford Biomedica said the pair had extended the terms of their commercial supply agreement to the end of 2028, with Oxford regaining the rights to its LentiVector platform relating to three CAR-T targets. Oxford Biomedica highlighted that it now also has the right to work with potential pharmaceutical and biotech partners other than Novartis across all CAR-T targets.
As of 0820 GMT, Oxford Biomedical shares were down 0.92% at 1,192.95p.